Canada Drugs Direct

Visiting from Canada?

Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.

I agree to receive email updates from Canada Drugs Direct

Looking for CanadaDrugsDirect.net? Call us toll free 1-800-500-2897

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

Prescription medicineOnly Available By Prescription
Sezzle

Top brand choice

Strength Pack Size Qty
Strength
100mg/300mg/300mg
Pack Size
Qty

You'll have option to make 4 interest-free payments by credit card once your order is confirmed using

What if I find a lower price with another pharmacy?

We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!

Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.

To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.

Terms & Conditions of Program

  • Guaranteed lowest price is only valid at the time of sale.
  • We will only match the current advertised price.
  • Products must be identical and in stock at the time of placing an order with a licensed mail order pharmacy. The must be a member of CIPA (Canadian International Pharmacy Association).
  • Products must be authentic in brand and size (same manufacturer, same country of manufacture, same pack size, same strength and same quantity).
  • Products must be new. We cannot match the price of any used, short expiry or expired product.
  • Price match can only be issued over the phone with our customer service team
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Description

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) is a three-in-one medication. It's indication is for treating HIV-1 infection in adults and pediatric patients who weigh at least 77 pounds (35 kilograms) and:

  • Have not received prior treatment for HIV-1 OR
  • Need to replace their current HIV-1 regimen upon meeting certain requirements per their doctor

Fact Table

Formula

C17H11ClF3N5O3

License

US DailyMed

Bioavailability

64%, 86%, 25%

Legal status

Rx-Only

Chemical Name

Doravirine, lamivudine, and tenofovir disoproxil fumarate

Elimination half-life

15 hrs

Dosage (Strength)

100mg/300mg/300mg

Pregnancy

Consult Doctor

Brands

Delstrigo

Protein binding

Around 75%

PubChem CID

-

MedlinePlus

a618049

ChEBI

-

ATC code

J05AR24

DrugBank

-

KEGG

D11396

Routes of administration

By mouth

Directions

Delstrigo is a tablet (100 mg doravirine/300 mg lamivudine/300 mg tenofovir disoproxil fumarate). 

The typical dose is one tablet by mouth one time a day. Delstrigo can be taken with or without food.

Your dose may be adjusted with the use of rifabutin.

Ingredients

Doravine (a non-nucleoside reverse transcriptase inhibitor), lamivudine (a nucleoside analogue reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleoside analogue reverse transcriptase inhibitor) are the active ingredients in Delstrigo.

Contraindications

You should not take Delstrigo if you are allergic to doravine, lamivudine, tenofovir disoproxil fumarate, or any of Delstrigo's ingredients.

You should not take Delstrigo if you are taking:

  • Carbamazepine
  • Oxcarbazepine
  • Phenobarbital
  • Phenytoin
  • Enzalutamide
  • Rifampin
  • Rifapentine
  • Mitotane
  • St. John's wort

Cautions

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B

See full prescribing information for complete boxed warning.

Severe acute exacerbations of hepatitis B (HBV) have been reported in patients coinfected with HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), two of the components of DELSTRIGO. Closely monitor hepatic function in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

  • Before you start treatment with Delstrigo, inform your doctor:
    • About all the medications you take. These include prescription, non-prescription, vitamins, and herbal supplements.
    • About your medical history and medical conditions, including hepatitis B infection, bone problems, or kidney problems.
    • If you are pregnant or plan to become pregnant
    • If you are currently nursing or plan to nurse your baby.
  • Immune system changes may occur with the use of Delstrigo. Your immune system may fight off infections that have been dormant in your body for some time. Tell your doctor right away if you develop new symptoms during treatment with Delstrigo. 

Side Effects

Delstrigo can cause side effects, including dizziness, unusual dreams, and nausea. 

Contact your doctor right away if you develop side effects that are bothersome or persistent.

References:

  1. Delstrigo Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2022.
  2. Delstrigo Patient Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2022.


IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

product-reviews Product Reviews